Epirus Biopharmaceuticals, Inc. (NASDAQ:EPRS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

0
Player Avatar Sn8keiis (< 20) Submitted: 1/2/2013 8:29:03 AM : Outperform Start Price: $3.96 EPRS Score: +88.74

Bargain price for a stock with HUGE potential. 1000 shares for less than a $1000 mitigates risk.

Featured Broker Partners


Advertisement